Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 5, 2026
Reporting period
Not applicable
Filed with the SEC
Aug 28, 2026
InsiderIndirect holdingOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000886982-26-000522
Filed / recorded
Aug 28, 2026, 9:38 PM UTC
Added to OQRO
Oct 2, 2026, 3:52 AM UTC
Parser
form4-xml-v1
Data quality
Needs review
Issuer
Attovia Therapeutics, Inc.
Issuer CIK
2058707
Ticker
ATTO
Reporting person
GOLDMAN SACHS GROUP INC
Relationship
Other
Security
Equity Swap
Table
Derivative (Table II)
Transaction date
Aug 5, 2026
Transaction code
P
Shares / units
5,744
Price per share
$21.22
Acquired / disposed
Acquired (A)
Shares owned after
105,807
Ownership form
Indirect — See Footnotes
Amendment
Yes (Form 4/A)
Footnotes from the filing
GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.
Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
Congress trade